BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 37204828)

  • 1. Understanding the Uptake and Outcomes of Non-occupational Postexposure Prophylaxis Use Through an Online Medical Platform in China: Web-Based Cross-sectional Study.
    Shan D; Xue H; Yu F; Zan X; Liu H; Liu J; Han M; Zhang D
    J Med Internet Res; 2023 May; 25():e42729. PubMed ID: 37204828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-retroviral Therapy Based HIV Prevention Among a Sample of Men Who Have Sex with Men in Cape Town, South Africa: Use of Post-exposure Prophylaxis and Knowledge on Pre-exposure Prophylaxis.
    Hugo JM; Stall RD; Rebe K; Egan JE; De Swardt G; Struthers H; McIntyre JA
    AIDS Behav; 2016 Dec; 20(Suppl 3):357-364. PubMed ID: 27631366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protocol for a multicenter, real-world study of HIV pre-exposure prophylaxis among men who have sex with men in China (CROPrEP).
    Wang H; Zhang Y; Mei Z; Jia Y; Leuba SI; Zhang J; Chu Z; Ding H; Jiang Y; Geng W; Shang H; Xu J
    BMC Infect Dis; 2019 Aug; 19(1):721. PubMed ID: 31416439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
    Mayer KH; Molina JM; Thompson MA; Anderson PL; Mounzer KC; De Wet JJ; DeJesus E; Jessen H; Grant RM; Ruane PJ; Wong P; Ebrahimi R; Zhong L; Mathias A; Callebaut C; Collins SE; Das M; McCallister S; Brainard DM; Brinson C; Clarke A; Coll P; Post FA; Hare CB
    Lancet; 2020 Jul; 396(10246):239-254. PubMed ID: 32711800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Use of HIV Pre- and Postexposure Prophylaxis Among a Web-Based Sample of HIV-Negative and Unknown Status Cisgender and Transgender Sexual Minority Men: Cross-sectional Study.
    John SA; Sizemore KM; Jimenez RH; Jones SS; Petroll AE; Rendina HJ
    JMIR Public Health Surveill; 2022 Dec; 8(12):e31237. PubMed ID: 36306518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The PrEP You Want: A Web-Based Survey of Online Cross-Border Shopping for HIV Prophylaxis Medications.
    Walmsley B; Gallant D; Naccarato M; Hull M; Smith A; Tan DH
    J Med Internet Res; 2019 Jul; 21(7):e12076. PubMed ID: 31333200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Status and associated factors of pre-exposure prophylaxis use among men who have sex with men in 24 cities in China].
    Pan L; Xue H; Yu F; Shan D; Zhang DP; Wang JJ
    Zhonghua Liu Xing Bing Xue Za Zhi; 2023 Jun; 44(6):905-911. PubMed ID: 37380411
    [No Abstract]   [Full Text] [Related]  

  • 8. HIV Preexposure Prophylaxis With Emtricitabine and Tenofovir Disoproxil Fumarate Among Cisgender Women.
    Marrazzo J; Tao L; Becker M; Leech AA; Taylor AW; Ussery F; Kiragu M; Reza-Paul S; Myers J; Bekker LG; Yang J; Carter C; de Boer M; Das M; Baeten JM; Celum C
    JAMA; 2024 Mar; 331(11):930-937. PubMed ID: 38427359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preexposure Prophylaxis for the Prevention of HIV: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Chou R; Spencer H; Bougatsos C; Blazina I; Ahmed A; Selph S
    JAMA; 2023 Aug; 330(8):746-763. PubMed ID: 37606667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PrEP Demonstration Project Showed Superior Adherence with Tenofovir Alafenamide/Emtricitabine Compared to Tenofovir Disoproxil Fumarate/Emtricitabine in a Sample of Partnered Sexual Minority Men.
    Robles G; Sauermilch D; Gandhi M; Starks TJ
    AIDS Behav; 2021 Apr; 25(4):1299-1305. PubMed ID: 33206262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Algorithms Used for PrEP Surveillance Using a Reference Population From New York City, July 2016-June 2018.
    Furukawa NW; Smith DK; Gonzalez CJ; Huang YA; Hanna DB; Felsen UR; Zhu W; Arnsten JH; Patel VV
    Public Health Rep; 2020; 135(2):202-210. PubMed ID: 32027559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-tablet regimen of emtricitabine/tenofovir disoproxil fumarate plus cobicistat-boosted elvitegravir increase adherence for HIV postexposure prophylaxis in sexual assault victims.
    Malinverni S; Bédoret F; Bartiaux M; Gilles C; De Wit S; Libois A
    Sex Transm Infect; 2021 Aug; 97(5):329-333. PubMed ID: 33106437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dolutegravir with tenofovir disoproxil fumarate-emtricitabine as HIV postexposure prophylaxis in gay and bisexual men.
    McAllister JW; Towns JM; Mcnulty A; Pierce AB; Foster R; Richardson R; Carr A
    AIDS; 2017 Jun; 31(9):1291-1295. PubMed ID: 28301425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acceptability of pre-exposure prophylaxis for HIV prevention: facilitators, barriers and impact on sexual risk behaviors among men who have sex with men in Benin.
    Ahouada C; Diabaté S; Mondor M; Hessou S; Guédou FA; Béhanzin L; Batona G; Gning NN; Zannou DM; Alary M
    BMC Public Health; 2020 Aug; 20(1):1267. PubMed ID: 32819335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of HIV Preexposure Prophylaxis With Incidence of Sexually Transmitted Infections Among Individuals at High Risk of HIV Infection.
    Traeger MW; Cornelisse VJ; Asselin J; Price B; Roth NJ; Willcox J; Tee BK; Fairley CK; Chang CC; Armishaw J; Vujovic O; Penn M; Cundill P; Forgan-Smith G; Gall J; Pickett C; Lal L; Mak A; Spelman TD; Nguyen L; Murphy DA; Ryan KE; El-Hayek C; West M; Ruth S; Batrouney C; Lockwood JT; Hoy JF; Hellard ME; Stoové MA; Wright EJ;
    JAMA; 2019 Apr; 321(14):1380-1390. PubMed ID: 30964528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal HIV Postexposure Prophylaxis Regimen Completion With Single Tablet Daily Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine Compared With More Frequent Dosing Regimens.
    Mayer KH; Jones D; Oldenburg C; Jain S; Gelman M; Zaslow S; Grasso C; Mimiaga MJ
    J Acquir Immune Defic Syndr; 2017 Aug; 75(5):535-539. PubMed ID: 28696345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Willingness to use long-acting injectable PrEP among HIV-negative/unknown men who have sex with men in mainland China: A cross-sectional online survey.
    Fu J; Dai Z; Wang H; Si M; Chen X; Wu Y; Xiao W; Huang Y; Yu F; Mi G; Su X
    PLoS One; 2023; 18(10):e0293297. PubMed ID: 37856527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial.
    Antoni G; Tremblay C; Delaugerre C; Charreau I; Cua E; Rojas Castro D; Raffi F; Chas J; Huleux T; Spire B; Capitant C; Cotte L; Meyer L; Molina JM;
    Lancet HIV; 2020 Feb; 7(2):e113-e120. PubMed ID: 31784343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-exposure prophylaxis: an underutilized biomedical HIV prevention method among gay, bisexual and other men who have sex with men in China.
    Hou J; Wu Y; Xie L; Meng S; Fu R; Zheng H; He N; Huang X; Xu J; Meyers K
    AIDS Care; 2020 Dec; 32(12):1573-1580. PubMed ID: 32188267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and threshold analysis.
    Jamieson L; Johnson LF; Nichols BE; Delany-Moretlwe S; Hosseinipour MC; Russell C; Meyer-Rath G
    Lancet HIV; 2022 Dec; 9(12):e857-e867. PubMed ID: 36356603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.